Close Menu

NEW YORK ─ Antegenes said on Wednesday that it has received CE marking for four polygenic risk score (PRS) tests ─ AnteBC for breast cancer, AntePC for prostate cancer, AnteCRC for colorectal cancer, and AnteMEL for melanoma.

The Estonia-based biotech company has launched the tests for use in the European Union and other countries that accept the designation.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.